review article | Q7318358 |
scholarly article | Q13442814 |
P2093 | author name string | Kevin J Barnham | |
Vijaya B Kenche | |||
P2860 | cites work | Donepezil for mild cognitive impairment | Q24245534 |
Memantine for dementia | Q24246560 | ||
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease | Q24298553 | ||
Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice | Q24530682 | ||
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization | Q28185520 | ||
Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism | Q28298521 | ||
Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity | Q28508433 | ||
Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts | Q28592548 | ||
A specific amyloid-beta protein assembly in the brain impairs memory | Q28854597 | ||
Alzheimer's disease is a synaptic failure | Q29547670 | ||
Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation | Q31154202 | ||
Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy | Q33335764 | ||
Pleomorphic copper coordination by Alzheimer's disease amyloid-beta peptide | Q33397015 | ||
Role of free radicals and metal ions in the pathogenesis of Alzheimer's disease. | Q33545519 | ||
Minding metals: tailoring multifunctional chelating agents for neurodegenerative disease | Q33813567 | ||
Alzheimer's disease, beta-amyloid protein and zinc | Q33913084 | ||
Alzheimer disease beta-amyloid activity mimics cholesterol oxidase | Q33925332 | ||
Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography | Q34016136 | ||
Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. | Q34082498 | ||
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial | Q34283745 | ||
Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. | Q48617420 | ||
Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential | Q48670684 | ||
An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". | Q48903618 | ||
Combating Alzheimer's disease with multifunctional molecules designed for metal passivation. | Q50691361 | ||
Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. | Q53222718 | ||
Copper catalyzed oxidation of Alzheimer Abeta. | Q53236205 | ||
Rapid induction of Alzheimer A beta amyloid formation by zinc. | Q53316140 | ||
Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships | Q56480906 | ||
The Aβ Peptide of Alzheimer's Disease Directly Produces Hydrogen Peroxide through Metal Ion Reduction† | Q58842885 | ||
Copper(II) bis(thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET | Q68097063 | ||
Effect of aldehydes derived from oxidative deamination and oxidative stress on beta-amyloid aggregation; pathological implications to Alzheimer's disease | Q80079185 | ||
Pulse EPR spectroscopy reveals the coordination sphere of copper(II) ions in the 1-16 amyloid-beta peptide: a key role of the first two N-terminus residues | Q84859058 | ||
Reaction of 3-ethoxy-2-oxobutyraldehyde bis(thiosemicarbazonato) Cu(II) with Ehrlich cells. Binding of copper to metallothionein and its relationship to zinc metabolism and cell proliferation | Q93633702 | ||
Design of small molecules that target metal-A{beta} species and regulate metal-induced A{beta} aggregation and neurotoxicity. | Q34438376 | ||
Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide | Q34456855 | ||
Redox processes of methionine relevant to beta-amyloid oxidation and Alzheimer's disease | Q34497903 | ||
Linker histone H1 binds to disease associated amyloid-like fibrils | Q34549177 | ||
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta | Q34793942 | ||
Copper and zinc binding to amyloid-beta: coordination, dynamics, aggregation, reactivity and metal-ion transfer | Q35010523 | ||
The metallobiology of Alzheimer's disease | Q35104793 | ||
The wide pharmacological versatility of semicarbazones, thiosemicarba-zones and their metal complexes. | Q35644524 | ||
Zn2+ ions: modulators of excitatory and inhibitory synaptic activity. | Q35883459 | ||
A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease | Q36329012 | ||
Copper homeostasis in the CNS: a novel link between the NMDA receptor and copper homeostasis in the hippocampus | Q36444326 | ||
Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease | Q36657466 | ||
The redox chemistry of the Alzheimer's disease amyloid beta peptide. | Q36791163 | ||
Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity | Q36925565 | ||
Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation | Q37061979 | ||
Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease | Q37564474 | ||
The challenges of determining metal-protein affinities | Q37727830 | ||
Neuropathology of unconventional virus infections: molecular pathology of spongiform change and amyloid plaque deposition | Q39518214 | ||
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial | Q40064054 | ||
Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity | Q40285493 | ||
Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis | Q40484248 | ||
The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis | Q41152552 | ||
Pathological alterations in the amygdala in Alzheimer's disease | Q41767135 | ||
Differential modulation of Alzheimer's disease amyloid beta-peptide accumulation by diverse classes of metal ligands. | Q42723254 | ||
Alzheimer's failure raises questions about disease-modifying strategies | Q42872330 | ||
fac-{Ru(CO)(3)}(2+) selectively targets the histidine residues of the beta-amyloid peptide 1-28. Implications for new Alzheimer's disease treatments based on ruthenium complexes | Q43066646 | ||
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses | Q43158585 | ||
Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease? | Q43174632 | ||
Deprotonation of the Asp1-Ala2 peptide bond induces modification of the dynamic copper(II) environment in the amyloid-beta peptide near physiological pH. | Q43244535 | ||
New evidence that the Alzheimer beta-amyloid peptide does not spontaneously form free radicals: an ESR study using a series of spin-traps. | Q43615257 | ||
Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta | Q44724513 | ||
Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid | Q44961994 | ||
Methionine regulates copper/hydrogen peroxide oxidation products of Abeta | Q45213980 | ||
Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity | Q45236656 | ||
Alanine-2 carbonyl is an oxygen ligand in Cu2+ coordination of Alzheimer's disease amyloid-beta peptide--relevance to N-terminally truncated forms. | Q45982880 | ||
A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. | Q46064935 | ||
Dimerisation of N-acetyl-L-tyrosine ethyl ester and Abeta peptides via formation of dityrosine | Q46813004 | ||
Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide | Q46845387 | ||
In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. | Q46979979 | ||
Characterizing bathocuproine self-association and subsequent binding to Alzheimer's disease amyloid beta-peptide by NMR. | Q47669111 | ||
Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer's disease | Q48302492 | ||
Copper, iron and zinc in Alzheimer's disease senile plaques | Q48429285 | ||
1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution. | Q48596573 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Alzheimer's disease | Q11081 |
P304 | page(s) | 211-219 | |
P577 | publication date | 2011-05-01 | |
P1433 | published in | British Journal of Pharmacology | Q919631 |
P1476 | title | Alzheimer's disease & metals: therapeutic opportunities | |
P478 | volume | 163 |
Q37459305 | A new paradigm for enzymatic control of α-cleavage and β-cleavage of the prion protein |
Q59333275 | Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease |
Q37020647 | Altered plasma marker of oxidative DNA damage and total antioxidant capacity in patients with Alzheimer's disease |
Q28488690 | Bapineuzumab alters aβ composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy |
Q38856393 | Biological and computational evaluation of resveratrol inhibitors against Alzheimer's disease. |
Q38067144 | Brain iron accumulation in aging and neurodegenerative disorders |
Q46426248 | Cardiac Light Chain Amyloidosis: The Role of Metal Ions in Oxidative Stress and Mitochondrial Damage. |
Q38022265 | Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. |
Q40441989 | Copper-zinc cross-modulation in prion protein binding |
Q38126969 | Design and optimization of drugs used to treat copper deficiency |
Q57184141 | Dual-function triazole-pyridine derivatives as inhibitors of metal-induced amyloid-β aggregation |
Q48043759 | Effect of Transition Metals on Polysialic Acid Structure and Functions |
Q39189574 | Exploring the multifunctionality of thioflavin- and deferiprone-based molecules as acetylcholinesterase inhibitors for potential application in Alzheimer's disease |
Q39187770 | Fragment-based discovery of 8-hydroxyquinoline inhibitors of the HIV-1 integrase-lens epithelium-derived growth factor/p75 (IN-LEDGF/p75) interaction |
Q52980546 | Insight into inhibition of the human amyloid beta protein precursor (APP: PDB ID ) using (E)-N-(pyridin-2-ylmethylene)arylamine (LR) models: structure elucidation of a family of ZnX2-LR complexes. |
Q48404452 | Introduction of a fluorescent probe to amyloid-β to reveal kinetic insights into its interactions with copper(II). |
Q41673954 | Kinetics of the Interactions between Copper and Amyloid-β with FAD Mutations and Phosphorylation at the N terminus. |
Q91781230 | Manganese-Induced Neurotoxicity: New Insights Into the Triad of Protein Misfolding, Mitochondrial Impairment, and Neuroinflammation |
Q51118986 | Modulating the microtubule-tau interactions in biomotility systems by altering the chemical environment. |
Q34199803 | Modulation of amyloid-β aggregation by histidine-coordinating Cobalt(III) Schiff base complexes. |
Q36652253 | Nanoprobing of the effect of Cu(2+) cations on misfolding, interaction and aggregation of amyloid β peptide |
Q26996127 | New perspectives on oxidized genome damage and repair inhibition by pro-oxidant metals in neurological diseases |
Q38127470 | Novel disease-modifying therapeutics for the treatment of Alzheimer's disease. |
Q93332761 | Overview and Current Status of Alzheimer's Disease in Bangladesh |
Q37101305 | Oxidative stress and the pathogenesis of Alzheimer's disease |
Q35148844 | Oxidative stress in neurodegenerative diseases |
Q39775009 | Promising in Vitro anti-Alzheimer Properties for a Ruthenium(III) Complex |
Q46755177 | Redox activity and multiple copper(I) coordination of 2His-2Cys oligopeptide |
Q46540770 | Resistance of Cu(Aβ4-16) to Copper Capture by Metallothionein-3 Supports a Function for the Aβ4-42 Peptide as a Synaptic Cu(II) Scavenger |
Q38961537 | Structure and Synaptic Function of Metal Binding to the Amyloid Precursor Protein and its Proteolytic Fragments |
Q38685683 | Supplementation with zinc in rats enhances memory and reverses an age-dependent increase in plasma copper |
Q58486506 | The Amyloid-β Peptide in Amyloid Formation Processes: Interactions with Blood Proteins and Naturally Occurring Metal Ions |
Q52938123 | The multiple conformational charge states of zinc(II) coordination by 2His-2Cys oligopeptide investigated by ion mobility-mass spectrometry, density functional theory and theoretical collision cross sections. |
Q59137339 | The social defeat/overcrowding murine psychosocial stress model results in a pharmacologically reversible body weight gain but not depression - related behaviours |
Q36339890 | Triplin, a small molecule, reveals copper ion transport in ethylene signaling from ATX1 to RAN1. |
Q39016079 | Zinc and Copper Differentially Modulate Amyloid Precursor Protein Processing by γ-Secretase and Amyloid-β Peptide Production |
Search more.